- Enterprise.
- Not disclosed
- Not disclosed
- —
- —
- Regulatory & Compliance0/28
No FDA clearance listed
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength0/28.8
No peer-reviewed coverage
- Vendor & Market3/18
market_relevance=55 (seed or unfunded)
- Sentiment & Transparency2.5/14
1 pricing tier(s) but no $ amounts (contact-sales pattern)
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/18
No FDA clearance listed
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers0/21
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
market_relevance=55 (seed or unfunded)
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
1 pricing tier(s) but no $ amounts (contact-sales pattern)
Last computed May 26, 2026 · Rubric v1.0.0
End-to-end digital pathology IMS with embedded AI ecosystem.
Free tier available.
We do not yet have enough independent sources for Lumea BxChange to publish a full editorial review. A complete review requires peer-reviewed coverage, clinician sentiment from public forums, or hands-on testing notes from our editorial team.
The vendor overview below reflects what we have verified from the vendor and from our category-level reporting. When additional sources surface, the review is regenerated automatically and dated. If you have direct hands-on experience and want to share it on the record, write to editorial@medaiverdict.com.
IMS + AI partner ecosystem.
What it costs
Free tier only; no paid plans publicly disclosed.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Plan | — | — | Enterprise. |
Source: vendor pricing page. Verified July 1, 2026.
Other pathology
See the full pathology ranking
Tempus Digital Pathology
by Tempus AI
Paige Predict 123-biomarker pan-cancer suite (Tempus acquired Paige 2025).
Enterprise + per-test.|FDA 510(k) / CE-IVDRPathAI AISight
by PathAI
Open IMS platform with AISight Dx + biopharma diagnostic services.
Enterprise.
Proscia Concentriq
by Proscia
Most-considered IMS platform, used by 16/20 top pharma.
Enterprise.
Ibex Medical Analytics
by Ibex
Most-deployed AI pathology platform globally.
Enterprise.
